News
Dexter Surgical Robot by Distalmotion Gains FDA Approval
Distalmotion’s Dexter Surgical Robot has officially received FDA approval for use in inguinal hernia repairs, introducing a transformative solution for outpatient surgery and Ambulatory Surgery Centers (ASCs) in the U.S. Known for its compact and mobile design, Dexter is set to meet the rising demand for cost-effective, robotic-assisted surgeries in high-volume settings. Dexter,…
Read MoreAdoram Therapeutics, ex vivo and Dyneo Technologies awarded by the FIF
Three Innovative Geneva start-ups Secure FIF financing to drive technological advances in Life Sciences, Virtual Reality for Medical Education and Cleantech The selected companies, Adoram Therapeutics, Dyneo Technologies and ex vivo, have received a combined total of 250,000 CHF in FIF funding, including Seed Loans and Grants, to advance their groundbreaking technologies and solutions.…
Read MoreDuhn Therapeutics signs global license agreement with OM Pharma
Duhn Therapeutics SAS, a clinical-stage company co-founded by Landmark BioVentures AG, and OM Pharma SA, a global biopharmaceutical company and leader in bacterial lysate products, announce an exclusive licence agreement to advance the development and commercialization of lead candidate DHN198, previously OM-174, in a pipeline of lipid-based cancer immunotherapies. Duhn Therapeutics, with executive…
Read MoreONWARD Medical raises CHF 50 million
ONWARD Medical N.V.announces that it successfully raised an amount of EUR 50 million led by a cornerstone investment from Ottobock, a German global leader in prosthetics, orthotics, and exoskeleton technology. The investment is extending the company’s cash runway to two years or more, providing ample capital to fuel its transition to a commercial enterprise, and…
Read More100 new jobs and a new plant for Lonza in Visp
Lonza is expanding its partnership with an undisclosed major pharmaceutical company to supply antibody-drug conjugates (ADCs). This agreement includes building a new facility at Lonza’s Ibex® Biopark in Visp, Switzerland, and providing large-scale production of monoclonal antibodies for a new ADC treatment. Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical…
Read MoredEEGtal awarded during the 18th HUG Innovation Day
Geneva University Hospitals (HUG) awarded the 2024 Innovation Prize to three projects: dEEGtal, an artificial intelligence-assisted biomarker for the early diagnosis of epilepsy; 3Dneointub8, a training device for nasotracheal intubation of infants; and Prestapp, a navigation aid for the healthcare network. As a bridge between the worlds of hospitals, universities and business, Innovation…
Read MoreAktiia Gets CE-mark Approval For CALFREE as a Class II medical product
Swiss healthcare technology company Aktiia has achieved a major milestone with the CE-mark approval of its groundbreaking CALFREE technology as a Class II medical product. This new technology allows for calibration-free blood pressure monitoring using optical sensors found in common devices like smartwatches and smartphone cameras, transforming the way blood pressure is tracked and managed.…
Read MoreFinalSpark’s Neuroplatform: the era of organic computing has begun!
Swiss startup FinalSpark has just launched its Neuroplatform, the world’s first commercial bioprocessor. This innovation promises to be a technological and energy revolution, with the potential to disrupt the field of artificial intelligence FinalSpark’s Neuroplatform: A Radical Approach What makes FinalSpark’s research groundbreaking is the fact that FinalSpark lab is fully accessible remotely, as…
Read MoreHealthCare Konnect and AI4MedImaging Announce Strategic Alliance
AI4MedImaging and HealthCare Konnect have formed a strategic alliance to extend the reach of AI4CMR, a fully automated cardiac MRI solution, through the powerful HCKonnect digital platform.
Read MoreLymphatica Medtech Closes € 17.9 M Series B Funding Round
Lymphatica Medtech SA, a clinical-stage company based in Lausanne, Switzerland, specialized in innovative treatments for lymphedema, has raised €17.9 million in Series B funding. This investment will accelerate the clinical development and validation of LymphoDrain, a breakthrough implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions…
Read More